Light‐Driven Quadrupedal Walking Biohybrid Robot With Antagonistic Muscle‐Rings and Inclined Joints
This work presents a light‐driven quadrupedal walking biohybrid robot powered by antagonistic muscle‐rings that achieve alternating walking gait. Optical training improved reproducibility of cultured muscle tissues, while caffeine treatment enhanced contractile force.
Shotaro Saito +5 more
wiley +1 more source
QSP-Copilot: An AI-Augmented Platform for Accelerating Quantitative Systems Pharmacology Model Development. [PDF]
Saini A, Farnoud A.
europepmc +1 more source
ELABELA Targets Mitochondria to Modulate Heart Development
The role of peptide ELABELA (ELA) in cardiomyocyte apoptosis and congenital heart disease (CHD) is unclear. ELA deficiency caused cardiomyocyte apoptosis and CHD. A novel ELA‐APJ‐AKT‐BCL2/BAX axis in regulating mitochondrial function and contributing to CHD pathogenesis was established.
Jian Wang +22 more
wiley +1 more source
Identification of predictive biomarkers and dose optimization for camrelizumab combined with apatinib in the treatment of advanced hepatocellular carcinoma: a quantitative systems pharmacology approach. [PDF]
Huang W +6 more
europepmc +1 more source
Development of a Quantitative Systems Pharmacology Model to Interrogate Mitochondrial Metabolism in Heart Failure [PDF]
Lyndsey F. Meyer +4 more
openalex +1 more source
Quantitative Systems Pharmacology: An Exemplar Model‐Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development [PDF]
Gabriel Helmlinger +13 more
openalex +1 more source
Antibody drug conjugates deliver their cytotoxic anti‐tubulin or topoisomerase I inhibitor payloads to tumors through cancer cell receptor targeting. The released drug payloads induce cellular changes that interact with radiotherapy resulting in radiosensitization that improves cancer cell kill and stimulates anti‐tumor immune responses.
Jacqueline Lesperance +17 more
wiley +1 more source
A quantitative systems pharmacology model for certolizumab pegol treatment in moderate-to-severe psoriasis. [PDF]
Coto-Segura P +12 more
europepmc +1 more source

